Full-profile pharmacokinetics, anticancer activity and toxicity of an extended release trivalent PEGylated irinotecan prodrug

• Main Authors: Shiwen Song (Author), Dong Sun (Author), Hong Wang (Author), Jinliang Wang (Author), Huijing Yan (Author), Xuan Zhao (Author), John Paul Fawcett (Author), Xin Xu (Author), Deqi Cai (Author), Jingkai Gu (Author)
• Format: Book
• Published: Elsevier, 2023-08-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Irinotecan is an anticancer topoisomerase I inhibitor that acts as a prodrug of the active metabolite, SN-38. Unfortunately, the limited utility of irinotecan is attributed to its pH-dependent stability, short half-life and dose-limiting toxicity. To address this problem, a novel trivalent PEGylated...